About Sushi repeat-containing protein SRPX2
Sushi repeat-containing protein SRPX2 (SRPX2) is a protein
from Homo sapiens identified by UniProt accession
O60687, 465 residues long.
MolForge cross-references it against 0 known binders and
164 disease associations.
Target properties
| Protein name | Sushi repeat-containing protein SRPX2 |
| UniProt accession | O60687 |
| Gene | SRPX2 |
| Organism | Homo sapiens |
| Length | 465 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (164)
Diseases linked to this target (Open Targets).
- Rolandic epilepsy - speech dyspraxia · score 0.57
- rolandic epilepsy-speech dyspraxia syndrome · score 0.37
- autism · score 0.12
- papillary thyroid carcinoma · score 0.09
- pachyonychia congenita · score 0.09
- pulmonary fibrosis · score 0.08
- oral squamous cell carcinoma · score 0.08
- pancreatic neoplasm · score 0.07
- melanoma · score 0.06
- neoplasm · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O60687-F1 | alphafold | PREDICTED | 86.76 | — |
Amino-acid sequence (465 residues)
MASQLTQRGA LFLLFFLTPA VTPTWYAGSG YYPDESYNEV YAEEVPQAPA LDYRVPRWCY TLNIQDGEAT CYSPKGGNYH SSLGTRCELS CDRGFRLIGR RSVQCLPSRR WSGTAYCRQM RCHALPFITS GTYTCTNGVL LDSRCDYSCS SGYHLEGDRS RICMEDGRWS GGEPVCVDID PPKIRCPHSR EKMAEPEKLT ARVYWDPPLV KDSADGTITR VTLRGPEPGS HFPEGEHVIR YTAYDRAYNR ASCKFIVKVQ VRRCPTLKPP QHGYLTCTSA GDNYGATCEY HCDGGYDRQG TPSRVCQSSR QWSGSPPICA PMKINVNVNS AAGLLDQFYE KQRLLIISAP DPSNRYYKMQ ISMLQQSTCG LDLRHVTIIE LVGQPPQEVG RIREQQLSAN IIEELRQFQR LTRSYFNMVL IDKQGIDRDR YMEPVTPEEI FTFIDDYLLS NQELTQRREQ RDICE
Explore Sushi repeat-containing protein SRPX2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets